Fate Therapeutics (FATE) Plans Offering of Common Stock

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. FLG
4. GMAB
5. ACCV
6. SPCX
7. XNCR
8. AZN
9. APO
10. META

Go back to Fate Therapeutics (FATE) Plans Offering of Common Stock

Fate Therapeutics Announces Proposed Public Offering of Common Stock

September 11, 2019 4:01 PM EDT

SAN DIEGO, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the Company or Fate Therapeutics) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has commenced an underwritten public offering of its common stock. Fate Therapeutics intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies, the manufacture of its clinical product candidates, the expansion of its cGMP compliant manufacturing operations, the conduct of preclinical research and development, and for general corporate... More